Wockhardt, a research based global pharmaceutical and biotech company, has spent Rs. 83 crore (6% to sales) and including capital expenditure is at 9% to sales in Research & Development (R&D) during the first half year of FY21.     

 

8 patents were filed during the quarter ended 30th September, 2020 and the cumulative filings till date stands at 3,173. The company was granted 14 patents during the quarter and now holds 742 patents.

 

The capital expenditure during the half year ended 30th September, 2020 was Rs. 62 crore. Wockhardt, on August 3rd, 2020 entered into an agreement with the UK Government to finish COVID-19 vaccines for which manufacturing will be undertaken at CP Pharmaceuticals, a subsidiary of Wockhardt based in Wrexham, North Wales. 

 

As per the terms of the agreement, the company has reserved manufacturing capacity to allow for the supply of multiple vaccines to the UK Government in its fight against COVID-19, including AZD1222, the vaccine co-invented by the University of Oxford and its spin-out company, Vaccitech and licensed by AstraZeneca.

 

In the UK, Wockhardt is one of the largest suppliers into the NHS for over 20 years, has had a presence in Wrexham for over two decades and employs over 400 people at its 612,000 square feet high-tech manufacturing facility.

 

The Emerging Market Business of the company stood at Rs. 308 crore in H1 FY21 (PY Rs. 276 crore). Emerging Market business contributed about 23% of the Global Revenue. The UK Business stood at Rs. 451 crore in H1 FY21 (PY Rs. 447 crore). UK Business contributed about 33% of Global Revenue.

 

India Business stood at Rs. 240 crore in H1 FY21 as compared to Rs. 471 crore in H1FY20. De-growth is mainly due to partially divested Branded Generic business. India Business contributed 18% of the Global Revenue. 

 

Irish Business stood at Rs. 67 crore in H1 FY21 (PY Rs. 77 crore). US Business stood at Rs. 213 crore in H1 FY21 as compared to Rs. 331 crore in H1 FY20. The US Business contributed 16% of the Global Revenue.